Pleuromutilin derivative containing 2-thio-4-thiazolidone side chain as well as preparation method and application of pleuromutilin derivative

By synthesizing truncated leptin derivatives containing 2-thio-4-thiazolidinone side chains, the problems of existing antibacterial drug resistance and poor antibacterial effect on MRSA are solved, and effective against a variety of bacteria is achieved Inhibition, especially Staphylococcus aureus and Streptococcus, has wide application prospects.

CN118894818AActive Publication Date: 2024-11-05LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410952695.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-05
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

Existing antibacterial drugs are prone to drug resistance and have limited antibacterial effects on certain bacteria such as MRSA, and lack effective novel antibacterial solutions.

Method used

The truncated leptin derivatives containing the side chain of 2-thio-4-thiazolidinone were synthesized, and compounds with high yields and good antibacterial activity were prepared through specific synthetic routes and reaction conditions for use as novel antibacterial drugs.

Benefits of technology

This compound has shown significant antibacterial activity against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus and drug-resistant bacteria MRSA, and has good application prospects, especially in the prevention and treatment of infectious diseases caused by bacteria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894818A_ABST
    Figure CN118894818A_ABST
Patent Text Reader

Abstract

The invention discloses a pleuromutilin derivative containing a 2-thio-4-thiazolidone side chain as well as a preparation method and application of the pleuromutilin derivative. The preparation method comprises the following steps: firstly, adding pleuromutilin and paratoluensulfonyl chloride into methyl tert-butyl ether, stirring and dropwise adding a sodium hydroxide solution, and performing reflux reaction to obtain an intermediate 1; then adding 2-thio-4-thiazolidone into acetonitrile, adding anhydrous potassium carbonate at room temperature, stirring for 20 minutes, then adding the intermediate 1, and stirring at room temperature to react for a certain time to obtain an intermediate 2; and finally, adding the intermediate 2 and acyl chloride with different group donors into dichloromethane, and stirring at room temperature for a certain time under the catalysis of triethylamine to obtain the pleuromutilin derivative containing the 2-thio-4-thiazolidone side chain. The pleuromutilin derivative containing the 2-thio-4-thiazolidone side chain and having good antibacterial activity is synthesized through a simple preparation process, the yield is high, the pleuromutilin derivative also has good antibacterial activity on drug-resistant bacteria, and the application prospect is good.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to a pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain, and a preparation method and application thereof. Background Art

[0003] Pleuromutilin is a diterpene compound with antibacterial activity. It is a tricyclic diterpene compound with a (5-6-8) tricyclic ring. This class of compounds inhibits bacterial protein synthesis at the ribosome level, acting on the 23SRNA of the bacterial ribosome 50S subunit, and the binding site is in the V domain of peptidyl transferase (PTC). Its ternary nucleus binds to the active pocket of the A site, while the side chain partially covers the P site where tRNA binds to the ribosome, achieving the purpose of antibacterial inhibition by inhibiting bacterial protein synthesis. Pleuromutilin compounds have a different antibacterial nucleus structure from the common clinical antibacterial nucleus, and are not prone to cross-resistance with other structural antibacterial drugs. The ester structure side chain of C-14 of pleuromutilin is the main site for chemical modification. Most of the studies on the structural modification of the C-14 side chain are to modify the C-22 position while retaining the ester structure.

[0004] As a special type of potential advantageous framework, thiazolidinone small molecule heterocyclic compounds have attracted the attention of researchers in the field of medicinal chemistry in recent years. 2-Thio-4-thiazolidinone, also known as rhodanine, has a wide range of pharmacological activities and has become a dominant framework in medicinal chemistry and is widely used in the construction of new drug molecular chemical frameworks. Its molecular structure is shown below:

[0005]

[0006] 2-Thio-4-thiazolidinone derivatives have rich pharmacological activities, such as antibacterial, anticancer, anti-tuberculosis, hypoglycemic, etc. They also play an important role in the fields of pharmaceuticals and medical materials, and they have inhibitory activity on various enzyme targets, such as hepatitis C virus NS5B polymerase, penicillin binding protein (PBP), HIV-1 integrase, RNA polymerase, etc. The synthesis of rhodanine derivative drugs mainly includes the reaction of the active methylene at the C-5 position. At the same time, the acidity of NH allows extensive substitution at the N-3 position, which can greatly improve its antibacterial activity and bioavailability. Summary of the invention

[0007] In view of the problems existing in the above-mentioned background technology, the present invention provides a truncated pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain and a preparation method and application thereof. The synthesized truncated pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain has good in vitro antibacterial activity and can be used to prevent and treat infectious diseases caused by bacteria in humans or animals.

[0008] In order to achieve the above object, the present invention adopts the following technical solution:

[0009] A pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain, the molecular structure of the compound is shown in the following formula (I):

[0010]

[0011] In the formula, the R group is selected from any one of the following groups:

[0012]

[0013] The specific groups of the compounds of the above structure are summarized as shown in Table 1:

[0014] Table 1 Compound numbers and specific groups

[0015]

[0016]

[0017] The present invention further provides a pharmaceutically acceptable salt of a pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain.

[0018] The present invention further provides a method for preparing a pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain, comprising the following steps:

[0019] (1) adding pleuromutilin and p-toluenesulfonyl chloride to methyl tert-butyl ether and mixing, adding sodium hydroxide solution dropwise under stirring, and after reflux reaction, cooling, washing and drying the reaction product to obtain an intermediate 1 having a structure shown in formula (II);

[0020]

[0021] (2) adding 2-thioxo-4-thiazolidinone to acetonitrile, adding anhydrous potassium carbonate and stirring at room temperature for a certain period of time, then adding the intermediate 1, stirring at room temperature for a certain period of time, and after the reaction is completed, quenching, extracting, drying, and purifying the reaction product to obtain the intermediate 2 with the structure represented by formula (III);

[0022]

[0023] (3) adding the intermediate 2 and the group donor acyl chloride to dichloromethane, stirring and reacting at room temperature for a certain time under the catalysis of triethylamine, quenching after the reaction is completed, extracting, drying and purifying the reaction product to obtain a pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain as shown in formula (I);

[0024]

[0025] In the formula, the R group is selected from any one of the following groups:

[0026]

[0027] Furthermore, in step (1), the molar volume ratio of the pleuromutilin, p-toluenesulfonyl chloride, methyl tert-butyl ether and sodium hydroxide solution is 10-12 mmol: 10-12 mmol: 10-15 mL: 2.5-2.8 mL, and the concentration of the sodium hydroxide solution is 10 mol / L.

[0028] Furthermore, in step (2), the molar volume ratio of the intermediate 1, 2-thioxo-4-thiazolidinone, potassium carbonate and acetonitrile is 5-9 mmol: 5-6 mmol: 6-10 mmol: 30-35 mL.

[0029] Furthermore, in step (2), the quenching, extraction, drying and purification methods of the reaction product are as follows: the reactant is quenched with a saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, dried with anhydrous sodium sulfate, and purified by column chromatography at a ratio of petroleum ether: ethyl acetate = 3:1 to 2:1.

[0030] Furthermore, in step (3), the molar volume ratio of the intermediate 2, the group donor acyl chloride, triethylamine and dichloromethane is 1-1.2 mmol: 1-1.5 mmol: 2-2.4 mmol: 5-7 mL.

[0031] Furthermore, in step (3), the quenching, extraction, drying and purification methods of the reaction product are as follows: the reactant is quenched with a saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, dried with anhydrous sodium sulfate, and purified by column chromatography at a ratio of petroleum ether: ethyl acetate = 4:1 to 2:1.

[0032] The present invention further provides a use of a pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain or a pharmaceutically acceptable salt of the pleuromutilin derivative in the preparation of an antibacterial drug for treating infectious diseases.

[0033] The present invention further provides an antibacterial drug, which comprises the above-mentioned pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain and one or more pharmaceutically acceptable carriers, excipients or diluents of the pleuromutilin derivative;

[0034] Or, the drug comprises a pharmaceutically acceptable salt of the above-mentioned pleuromutilin derivative and one or more pharmaceutically acceptable carriers, excipients or diluents for the salt.

[0035] Compared with the shortcomings and deficiencies of the prior art, the present invention has the following beneficial effects:

[0036] The present invention synthesizes a large number of pleuromutilin derivatives with a new structure and a 2-thio-4-thiazolidinone side chain through a simple preparation process, and the yield is high. Through the screening of antibacterial activity, it is found that the compounds have good in vitro antibacterial activity, are particularly suitable as new antibacterial drugs for preventing and treating infectious diseases caused by bacteria in humans or animals, especially for Gram-positive bacteria such as Staphylococcus aureus and Streptococcus, and also have good antibacterial activity against drug-resistant bacteria MRSA. Therefore, the pleuromutilin derivatives prepared by the present invention have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 is the nuclear magnetic resonance spectrum of the pleuromutilin derivative 4 containing a 2-thio-4-thiazolidinone side chain provided in an embodiment of the present invention;

[0038] Figure 2 is the nuclear magnetic resonance spectrum of the pleuromutilin derivative 8 containing a 2-thio-4-thiazolidinone side chain provided in an embodiment of the present invention;

[0039] Figure 3 The bactericidal kinetic curves of the pleuromutilin derivative 19 containing a 2-thio-4-thiazolidinone side chain and tiamulin (T) against MRSA provided in the embodiments of the present invention are shown. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0041] Example 1

[0042] Preparation of intermediate 1:

[0043] 18.93g (0.05mol) of pleuromutilin and 11.22g (0.05mol) of p-toluenesulfonyl chloride were added to 50mL of methyl tert-butyl ether, stirred evenly, and then 13.5mL of 10mol / L sodium hydroxide solution was slowly added dropwise. After the addition was completed, the temperature was raised to 58°C and refluxed. The mixture was stirred vigorously for 1h, and a large amount of white solid appeared. After the reaction was completed, 100mL of 0-4°C ultrapure water was added and stirred vigorously. The white solid obtained by suction filtration was rinsed three times with 0-4°C ultrapure water, and the white solid was vacuum dried at 55°C to obtain the intermediate 1 having the structure shown in formula (II) with a yield of 94%. It can be used directly in the next step without purification.

[0044]

[0045] Example 2

[0046] Preparation of Intermediate 2:

[0047] 0.67 g (5 mmol) of 2-thioxo-4-thiazolidinone was added to 30 mL of acetonitrile, and 0.83 g (6 mmol) of anhydrous potassium carbonate was added under stirring at room temperature. After stirring for 20 min, 2.66 g (5 mmol) of intermediate 1 was added and stirred at room temperature for 4 to 5 h. After the reaction was completed, saturated sodium bicarbonate aqueous solution was used for quenching, dichloromethane was extracted, and the mixture was dried over anhydrous sodium sulfate. Column chromatography was performed to purify the mixture according to the ratio of petroleum ether to ethyl acetate = 2:1 to obtain intermediate 2 with a structure shown in formula (III) with a yield of 73%.

[0048]

[0049] 1 H NMR (400MHz, CDCl3) δ6.39 (dd, J=17.4, 11.0Hz, 1H), 5.74 (d, J=8.5Hz, 1H), 5.32-5 .24(m,1H),5.17(dd,J=17.4,1.6Hz,1H),4.15-3.90(m,4H),3.33(d,J=6.4Hz,1H) ,2.31-2.14(m,3H),2.12-2.02(m,2H),1.78-1.71(m,1H),1.70-1.46(m,5H),1.39 (d,J=22.4Hz,5H),1.18-1.05(m,4H),0.85(d,J=7.0Hz,3H),0.71(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.12,200.41,186.71,165.87,138.97,117.49,74.78,71.15,58.23,45.62,44.61,44.17,4 2.04,40.26,36.86,36.68,36.18,34.65,30.57,27.02,26.48,25.01,17.04,15.01,11.72.HRMS(ESI):calcd[M+Na] + for C 25 H 35 NO5S2516.1848,found,516.1838.

[0050] Example 3

[0051] Preparation of pleuromutilin derivatives 1 to 28 containing 2-thio-4-thiazolidinone side chain:

[0052] 1 mmol of the intermediate 2 prepared in Example 2 was dissolved in 6 mL of dichloromethane, 2 mmol of triethylamine was added, and 1.1 mmol of different group donor acyl chlorides were added under stirring at room temperature. The reaction was stirred at room temperature for 2 h, quenched with saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, purified by column chromatography (petroleum ether: ethyl acetate = 4:1-2:1), and concentrated to obtain target compounds 1-28;

[0053] Among them, the group donor acyl chlorides in the above reaction process are: cyclopropanecarbonyl chloride, cyclobutanecarbonyl chloride, cyclopentanecarbonyl chloride, cyclohexanecarbonyl chloride, hexanecarbonyl chloride, octanoyl chloride, n-butyryl chloride, p-chlorobenzoyl chloride, o-chlorobenzoyl chloride, 2,4,6-trichlorobenzoyl chloride, 2,2-dimethylbutyryl chloride, benzoyl chloride, o-methylbenzoyl chloride, m-methylbenzoyl chloride, p-methylbenzoyl chloride, m-chlorobenzoyl chloride, 2-thiophenecarbonyl chloride, isovaleryl chloride, pivaloyl chloride, 2-ethylhexanecarbonyl chloride, 3,3-dimethylbutyryl chloride, p-fluorobenzoyl chloride, 3-fluorobenzoyl chloride, o-bromobenzoyl chloride, m-bromobenzoyl chloride, o-fluorobenzoyl chloride, 3-methoxybenzoyl chloride, and 2,4-dichlorobenzoyl chloride.

[0054] The synthetic route is shown below:

[0055]

[0056] Pleuromutilin derivative 1

[0057] 1 H NMR (400MHz, CDCl3) δ6.96 (d, J=1.7Hz, 1H), 6.39 (dd, J=17.4, 11.0Hz, 1H), 5 .72(d,J=8.5Hz,1H),5.33-5.25(m,1H),5.15(d,J=17.4Hz,1H),3.90(t,J=2 .1Hz,2H),3.48-3.23(m,2H),2.44-2.17(m,7H),2.09-1.93(m,4H),1.77-1. 24(m,11H),1.18-1.05(m,4H),0.85(d,J=6.9Hz,3H),0.69(d,J=7.0Hz,3H). 13C NMR (101MHz, CDCl3) δ217.21,172.30,167.00,160.40,153.71,139.04,117.45,103.04,74.81,70.48,58.33,45.64,44.80,44.15, 42.05,38.13,36.92,36.73,36.21,34.67,30.61,27.05,26.65,25.45,25.04,18.60,16.96,15.02,11.70.HRMS(ESI):calcd[M+Na] + for C 30 H 41 NO6S2 598.2267,found,598.2247.

[0058] Pleuromutilin derivative 2

[0059] 1 H NMR (400MHz, CDCl3) δ6.94 (s, 1H), 6.41 (dd, J = 17.4, 11.0Hz, 1H), 5.73 (d, J =8.4Hz,1H),5.29(d,J=10.7Hz,1H),5.16(d,J=17.4Hz,1H),3.91(t,J=2.0H z,2H),3.33(d,J=6.4Hz,1H),2.52(t,J=7.5Hz,2H),2.34-1.98(m,5H),1.77 -1.26(m,17H),1.19-1.06(m,4H),0.96-0.80(m,6H),0.69(d,J=6.8Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.21,170.71,167.02,160.49,153.59,139.07,117.49,103.11,74.84,70.50,58.35,45.67,44.82,44.18,42.08, 36.95,36.76,36.24,34.69,34.39,31.41,30.63,27.08,26.65,25.07,24.55,22.53,17.00,15.05,14.15,11.73.HRMS(ESI):calcd[M+Na] + for C 31 H 45 NO6S2614.2580, found, 614.2546.

[0060] Pleuromutilin derivative 3

[0061] 1 H NMR(400MHz, CDCl3) δ6.94(s,1H),6.41(dd,J=17.4,11.0Hz,1H),5.73(d,J=8.5 Hz,1H),5.29(d,J=11.0Hz,1H),5.16(d,J=17.4Hz,1H),3.91(s,2H),3.33(d,J= 6.2Hz,1H),2.51(t,J=7.3Hz,2H),2.35-2.03(m,5H),1.80-1.30(m,13H),1.17- 1.06(m,4H),1.00(t,J=7.4Hz,3H),0.85(d,J=6.9Hz,3H),0.70(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.20,170.51,167.01,160.50,153.57,139.08,117.47,103.11,74.83,70.49,58.35,45.67,44.82,44. 18,42.08,36.94,36.75,36.24,34.69,30.63,27.07,26.66,25.06,18.39,16.99,15.04,13.83,11.72.HRMS(ESI):calcd[M+Na] + for C 29 H 41 NO6S2586.2267, found, 586.2249.

[0062] Pleuromutilin derivative 4

[0063] 1 H NMR (400MHz, CDCl3) δ6.93(s,1H),6.40(dd,J=17.5,11.0Hz,1H),5.72(d,J=8.4Hz,1H),5.31-5.26(m,1H),5.15(dd,J=17.5,1.6Hz,1H),3.90(d,J=2. 3Hz,2H),3.37-3.27(m,1H),2.52(t,J=7.6Hz,2H),2.33-1.97(m,5H),1.76 -1.26(m,21H),1.17-1.03(m,4H),0.94-0.82(m,6H),0.69(d,J=7.0Hz,3H). 13C NMR (101MHz, CDCl3) δ217.16,170.68,166.99,160.47,153.57,139.07,1 17.45,103.08,74.82,70.48,58.33,45.65,44.80,44.16,42.06,36.93, 36.74,36.23,34.67,34.41,31.83,30.62,29.20,29.11,27.06,26.66,2 5.05,24.84,22.81,16.98,15.03,14.31,11.71.HRMS(ESI):calcd[M+Na] + forC 33 H 49 NO6S2642.2893, found, 642.2863.

[0064] The NMR spectra of its pleuromutilin derivatives are as follows Figure 1 shown.

[0065] Pleuromutilin derivative 5

[0066] 1 H NMR (400MHz, CDCl3) δ6.92(s,1H),6.40(dd,J=17.4,11.0Hz,1H),5.73(d,J=8.4Hz,1H),5.29(d,J=11.0Hz,1H),5.15(d,J=17.4Hz,1H),3.91( t,2H),3.33(s,1H),2.36-2.11(m,3H),2.09-1.97(m,3H),1.84-1.32(m ,11H),1.18-0.97(m,8H),0.85(d,J=6.9Hz,3H),0.70(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.20,171.94,166.99,160.41,153.57,139.05,117.45,103.13,74.81,70.47,58.33,45.65,44.78,44. 15,42.06,36.93,36.73,36.22,34.67,30.61,27.05,26.64,25.04,16.97,15.03,13.11,11.71,9.96.HRMS(ESI):calcd[M+Na] + for C 29 H 39 NO6S2584.2111, found, 584.2108.

[0067] Pleuromutilin derivative 6

[0068] 1 H NMR (400MHz, CDCl3) δ6.95 (s, 1H), 6.41 (dd, J = 17.4, 11.0Hz, 1H), 5.73 (d, J = 8.4 Hz,1H),5.30(d,J=11.1Hz,1H),5.16(d,J=17.4Hz,1H),3.92(t,J=2.1Hz,2H),3. 33(d,J=6.4Hz,1H),3.02-2.85(m,1H),2.37-2.14(m,3H),2.09-1.88(m,6H),1.7 8-1.26(m,15H),1.21-1.04(m,4H),0.86(d,J=6.8Hz,3H),0.70(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.23,173.74,167.06,160.36,153.87,139.07,117.53,103.06,74.86,70.50,58.37,45.68,44.85,44.19, 43.97,42.09,36.96,36.79,36.25,34.70,30.64,30.28,27.08,26.67,26.12,25.08,17.01,15.06,11.74.HRMS(ESI):calcd[M+Na] + forC 31 H 43 NO6S2612.2424, found, 612.2352.

[0069] Pleuromutilin derivative 7

[0070] 1 H NMR (400MHz, CDCl3) δ6.94 (s, 1H), 6.40 (dd, J = 17.3, 11.0Hz, 1H), 5.72 (d, J = 8. 4Hz,1H),5.29(d,J=8.5Hz,1H),5.15(d,J=17.4Hz,1H),3.98-3.84(m,2H),3.33 (d,J=6.4Hz,1H),2.61-2.44(m,1H),2.32-2.15(m,3H),2.08-1.97(m,4H),1.83 -1.25(m,19H),1.17-1.04(m,4H),0.84(d,J=6.9Hz,3H),0.69(d,J=6.8Hz,3H).13 C NMR (101MHz, CDCl3) δ217.21,172.87,167.01,160.32,153.77,139.04,117.46,102.97,74.81,70.46,58.33,45.64,44.79,44.15,43. 33,42.05,36.91,36.74,36.21,34.66,30.60,29.02,27.04,26.66,25.82,25.48,25.04,16.97,15.02,11.70.HRMS(ESI):calcd[M+Na] + for C 32 H 45 NO6S2626.2580, found, 626.2556.

[0071] Pleuromutilin derivative 8

[0072] 1 H NMR(400MHz, CDCl3)δ8.11(d,J=8.3Hz,2H),7.47(d,J=8.2Hz,2H),7.10(s,1H), 6.41(dd,J=17.4,11.0Hz,1H),5.74(d,J=8.4Hz,1H),5.32-5.25(m,1H),5.14(d, J=17.4Hz,1H),4.03-3.85(m,2H),3.32(d,J=6.5Hz,1H),2.37-2.04(m,5H),1.7 8-1.30(m,11H),1.17-1.02(m,4H),0.85(d,J=6.9Hz,3H),0.71(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.19,166.97,162.82,160.92,153.39,140.87,139.07,131.91,129.31,127.26,117.49,103.67,74.82,70.55,5 8.34,45.66,44.82,44.18,42.09,36.93,36.77,36.25,34.69,30.62,27.07,26.66,25.06,17.01,15.06,11.72.HRMS(ESI):calcd[M+Na] + forC 32 H 38 ClNO6S2654.1721,found,654.1710.

[0073] The NMR spectra of its pleuromutilin derivatives are as follows Figure 2 shown.

[0074] Pleuromutilin derivative 9

[0075] 1 H NMR (400MHz, CDCl3) δ7.26-7.00(m,3H),6.26(dd,J=17.2,11.0Hz,1H),5.59(d,J=8.2Hz,1H),5.15-4.93(m,2H),3.80(t,2H),3.17(d,J=6.5Hz, 1H),2.25-2.01(m,3H),1.98-1.81(m,2H),1.66-1.41(m,4H),1.36-1.15 (m,7H),1.02-0.89(m,4H),0.71(d,J=7.1Hz,3H),0.55(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.20,167.01,161.34,160.79,152.71,139.01,137.36,133.31,130.95,128.46,117.54,103.73,74.85,70.59,5 8.35,45.68,44.86,44.17,42.09,36.94,36.71,36.23,34.71,30.64,27.07,26.55,25.07,17.02,15.06,11.74.HRMS(ESI):calcd[M+Na] + for C 32 H 36 Cl3NO6S2722.0941,found,722.0918.

[0076] Pleuromutilin derivative 10

[0077] 1H NMR (400MHz, CDCl3) δ8.14 (dd, J=8.1, 1.5Hz, 1H), 7.47 (td, J=7.5, 1.4Hz, 1H), 7.35-7.28 (m, 2H) ,7.05(s,1H),6.42(dd,J=17.4,11.0Hz,1H),5.74(d,J=8.4Hz,1H),5.30(d,J=1.5Hz,1H),5.13(d d,J=17.4,1.6Hz,1H),4.03-3.86(m,2H),3.32(d,J=6.5Hz,1H),2.65(s,3H),2.34-2.16(m,3H), 2.09-1.99(m,2H),1.78-1.31(m,11H),1.09(s,4H),0.85(d,J=6.9Hz,3H),0.71(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.22,167.04,164.03,160.64,153.75,141.98,13 9.02,133.41,132.24,131.64,127.61,126.19,117.50,103.60,74.81,70. 48,58.33,45.65,44.79,44.15,42.07,36.93,36.80,36.22,34.68,30.61, 27.04,26.59,25.05,22.22,17.00,15.05,11.73.HRMS(ESI):calcd[M+Na] + forC 33 H 41 NO6S2 634.2267,found,634.2234.

[0078] Pleuromutilin derivative 11

[0079] 1 H NMR (400MHz, CDCl3) δ6.91 (s, 1H), 6.48-6.35 (m, 1H), 5.72 (d, J = 8.5Hz, 1H ),5.30(d,J=11.1Hz,1H),5.16(d,J=17.4Hz,1H),3.99-3.84(m,2H),3.33( d,J=6.4Hz,1H),2.33-2.16(m,3H),2.07-2.02(m,2H),1.79-1.29(m,13H) ,1.27(s,6H),1.16-1.06(m,4H),0.96-0.82(m,6H),0.69(d,J=6.9Hz,3H).13 C NMR (101MHz, CDCl3) δ217.21,175.09,167.12,160.28,154.05,139.05,117.55,103.16,74.84,70.49,58.36,45.67,44.89,44.20,43. 48,42.09,36.95,36.81,36.24,34.70,33.50,30.64,27.07,26.69,25.07,24.75,17.01,15.04,11.73,9.55.HRMS(ESI):calcd[M+Na] + for C 31 H 45 NO6S2 614.2580,found,614.2535.

[0080] Pleuromutilin derivative 12

[0081] 1 H NMR (400MHz, CDCl3) δ8.17(d,J=7.4Hz,2H),7.63(t,J=7.3Hz,1H),7.49(t,J=7.7Hz,2H),7.09(d,J =0.9Hz,1H),6.41(dd,J=17.4,11.0Hz,1H),5.73(d,J=8.4Hz,1H),5.28(d,J=11.0Hz,1H),5.13(d, J=17.4Hz,1H),4.03-3.87(m,2H),3.31(d,J=6.3Hz,1H),2.33-2.15(m,3H),2.10-2.00(m,2H),1.7 9-1.45(m,6H),1.44-1.31(m,5H),1.14-1.04(m,4H),0.84(d,J=6.9Hz,3H),0.71(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.18,166.97,163.64,160.69,153.64,139.04,134.23,130.53,128.86,128.78,117.45,103.57,74.79,70.51,5 8.32,45.64,44.79,44.15,42.07,36.92,36.77,36.22,34.66,30.60,27.04,26.63,25.04,16.97,15.03,11.69.HRMS(ESI):calcd[M+Na] + for C 32 H39 NO6S2598.2291, found, 598.2272.

[0082] Pleuromutilin derivative 13

[0083] 1 H NMR (400MHz, CDCl3) δ8.00(d,J=8.0Hz,2H),7.23(d,J=8.0Hz,2H),7.03(s,1H),6.36(dd, J=17.4,11.0Hz,1H),5.68(d,J=8.4Hz,1H),5.23(d,J=10.9Hz,1H),5.08(d,J=17.2Hz,1H ),3.96-3.80(m,2H),3.26(d,J=6.5Hz,1H),2.38(s,3H),2.29-2.09(m,3H),2.00-1.93(m ,2H),1.73-1.25(m,11H),1.10-0.98(m,4H),0.79(d,J=7.0Hz,3H),0.65(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.23,167.04,163.72,160.57,153.80,145.20,139.04,130.62,129.62,126.03,117.53,103.48,74.85,70.52,58.3 7,45.68,44.83,44.19,42.10,36.96,36.82,36.25,34.70,30.65,27.07,26.63,25.08,22.06,17.01,15.07,11.73.HRMS(ESI):calcd[M+Na] + for C 33 H 41 NO6S2 634.2267,found,634.2256.

[0084] Pleuromutilin derivative 14

[0085] 1H NMR (400MHz, CDCl3) δ8.15(t,J=1.9Hz,1H),8.05(dt,J=7.8,1.3Hz,1H),7.64-7.59(m,1H),7.44( t,J=7.9Hz,1H),7.10(s,1H),6.42(dd,J=17.4,11.0Hz,1H),5.74(d,J=8.5Hz,1H),5.29(d,J=10.7 Hz,1H),5.14(d,J=17.4Hz,1H),4.01-3.87(m,2H),3.32(d,J=6.5Hz,1H),2.32-2.17(m,3H),2.11 -2.03(m,2H),1.78-1.31(m,11H),1.15-1.04(m,4H),0.85(d,J=7.0Hz,3H),0.72(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.17,166.96,162.47,161.02,153.29,139.08,1 35.11,134.29,130.56,130.51,130.24,128.66,117.49,103.71,74.82, 70.57,58.35,45.67,44.82,44.19,42.10,36.94,36.76,36.26,34.69,3 0.63,27.08,26.65,25.07,17.02,15.07,11.72.HRMS(ESI):calcd[M+Na] + for C 32 H 38 ClNO6S2654.1721,found,654.1710.

[0086] Pleuromutilin derivative 15

[0087] 1H NMR (400MHz, CDCl3) δ7.97(d,J=3.7Hz,1H),7.68(d,J=4.9Hz,1H),7.16(t,J=4.4Hz,1H),7.0 6(s,1H),6.41(dd,J=17.4,11.0Hz,1H),5.73(d,J=8.5Hz,1H),5.29(d,J=6.6Hz,1H),5.14(d d,J=17.4,1.5Hz,1H),4.03-3.84(m,2H),3.32(d,J=6.4Hz,1H),2.33-2.16(m,3H),2.09-1.9 8(m,2H),1.76-1.31(m,11H),1.17-1.04(m,4H),0.85(d,J=7.0Hz,3H),0.71(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.21,167.00,160.77,159.11,153.22,139.03,135.51,134.55,131.98,128.41,117.51,103.67,74.82,70.53,5 8.35,45.66,44.83,44.17,42.08,36.95,36.77,36.23,34.69,30.63,27.06,26.63,25.06,17.01,15.06,11.72.HRMS(ESI):calcd[M+Na] + for C 30 H 37 NO6S3626.1675, found, 626.1658.

[0088] Pleuromutilin derivative 16

[0089] 1 H NMR (400MHz, CDCl3) δ6.95 (s, 1H), 6.40 (dd, J = 17.4, 11.0Hz, 1H), 5.73 (d, J = 8.5Hz ,1H),5.33-5.25(m,1H),5.16(dd,J=17.4,1.6Hz,1H),3.91(s,2H),3.33(s,1H),2. 41(d,J=7.1Hz,2H),2.31-2.16(m,3H),2.10-2.03(m,2H),1.80-1.31(m,12H),1.1 7-1.08(m,4H),1.01(d,J=6.7Hz,6H),0.85(d,J=7.0Hz,3H),0.69(d,J=7.0Hz,3H). 13C NMR (101MHz, CDCl3) δ217.19,169.91,167.01,160.48,153.55,139.06,117.47,103.08,74.82,70.47,58.33,45.65,44.81,44.16, 43.32,42.06,36.92,36.73,36.23,34.68,30.62,27.06,26.66,25.85,25.05,22.61,16.98,15.03,11.72.HRMS(ESI):calcd[M+Na] + forC 30 H 43 NO6S2600.2424, found, 600.2429.

[0090] Pleuromutilin derivative 17

[0091] 1 H NMR (400MHz, CDCl3) δ6.94 (s, 1H), 6.41 (dd, J = 17.4, 11.0Hz, 1H), 5.73 (d, J = 8 .4Hz,1H),5.31(d,J=1.5Hz,1H),5.16(dd,J=17.4,1.6Hz,1H),3.92(s,2H),3. 33(t,J=7.7Hz,1H),2.41(s,2H),2.32-2.16(m,3H),2.12-1.99(m,2H),1.77-1 .28(m,11H),1.17-1.00(m,13H),0.85(d,J=7.0Hz,3H),0.69(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.19,169.12,167.05,160.44,153.54,139.05,117.51,103.16,74.83,70.47,58.34,47.77,45.66,44.83, 44.18,42.07,36.93,36.75,36.23,34.69,31.32,30.63,29.82,27.07,26.67,25.06,17.01,15.04,11.73.HRMS(ESI):calcd[M+Na] + forC 30 H 43 NO6S2600.2424, found, 600.2415.

[0092] Pleuromutilin derivative 18

[0093] 1 H NMR (400MHz, CDCl3) δ6.97 (s, 1H), 6.41 (dd, J = 17.4, 11.0Hz, 1H), 5.73 (d, J = 8. 4Hz,1H),5.30(d,J=11.1Hz,1H),5.16(dd,J=17.4,1.4Hz,1H),3.92(s,2H),3. 33(d,J=6.5Hz,1H),2.53-2.45(m,1H),2.34-2.16(m,3H),2.09-1.98(m,2H),1 .80-1.22(m,19H),1.19-1.06(m,4H),0.98-0.83(m,9H),0.70(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.21,173.35,167.09,160.33,153.77,139.03,1 17.55,103.00,74.84,70.48,58.35,47.50,45.67,44.87,44.18,42.08, 36.94,36.79,36.23,34.69,31.68,30.63,29.77,27.07,26.67,25.49,2 5.06,22.87,17.01,15.03,14.21,12.04,11.74.HRMS(ESI):calcd[M+Na] + forC 38 H 49 NO6S2642.2893, found, 642.2871.

[0094] Pleuromutilin derivative 19

[0095] 1 H NMR (400MHz, CDCl3) δ6.92(s,1H),6.49-6.35(m,1H),5.72(d,J=8.7Hz,1H),5.30(d,J=11.1Hz,1H),5.16(d,J=17.4Hz,1H),4.00-3.82(m,2 H),3.33(s,1H),2.35-2.18(m,3H),2.10-1.99(m,2H),1.75-1.32(m,20H),1.18-1.03(m,4H),0.85(d,J=7.1Hz,3H),0.70(d,J=6.4Hz,3H). 13C NMR (101MHz, CDCl3) δ217.19,175.54,167.09,160.28,154.04,139.04,117.54,103.19,74.82,70.48,58.35,45.66,44.87,44. 19,42.08,39.52,36.94,36.81,36.24,34.69,30.63,27.27,27.07,26.69,25.06,17.01,15.04,11.73.HRMS(ESI):calcd[M+Na] + for C 31 H 45 NO6S2614.2580,found,614.2542.

[0096] Pleuromutilin derivative 20

[0097] 1 H NMR (400MHz, CDCl3) δ8.25-8.15(m,2H),7.21-7.11(m,2H),7.09(s,1H),6.48-6.3 6(m,1H),5.74(d,J=8.5Hz,1H),5.30(d,J=1.6Hz,1H),5.14(dd,J=17.5,1.6Hz,1H) ,4.04-3.86(m,2H),3.33(d,J=6.5Hz,1H),2.36-2.14(m,3H),2.12-1.99(m,2H),1 .79-1.26(m,11H),1.15-1.03(m,4H),0.85(d,J=7.0Hz,3H),0.71(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.05, 166.77, 166.37 (d, J = 256.1Hz), 162.46, 160.63, 153.24, 138.8 0,133.00(d,J=9.6Hz),129.98(d,J=9.4Hz),125.69(d,J=3.1Hz),124.81(d,J=3.1Hz),117.2 9,115.96(d,J=22.1Hz),103.41,74.59,70.29,58.11,45.43,44.56,43.93,41.86,36.70,36 .55,36.00,34.46,30.39,26.83,26.39,24.82,16.78,14.82,11.50.HRMS(ESI):calcd[M+Na] + for C32 H 38 FNO6S2638.2016,found,638.2012.

[0098] Pleuromutilin derivative 21

[0099] 1 H NMR (400MHz, CDCl3) δ7.97 (dt, J=7.7, 1.3Hz, 1H), 7.90-7.81 (m, 1H), 7.52-7.44 (m, 1H), 7.41-7.3 1(m,1H),7.10(s,1H),6.42(dd,J=17.4,11.0Hz,1H),5.74(d,J=8.4Hz,1H),5.30(d,J=1.5Hz,1H) ,5.14(dd,J=17.4,1.5Hz,1H),4.03-3.86(m,2H),3.32(t,J=7.3Hz,1H),2.37-2.15(m,3H),2.09- 1.98(m,2H),1.79-1.31(m,11H),1.17-1.05(m,4H),0.85(d,J=7.0Hz,3H),0.71(d,J=6.9Hz,3H). 13 C NMR(101MHz, CDCl3)δ217.21,166.96,162.80(d,J=247.9Hz),162.54(d,J=3.3Hz),160.99,1 53.31,139.05,130.92(d,J=7.6Hz),130.60(d,J=7.8Hz),126.31(d,J=3.2Hz),121.41(d,J=2 1.2Hz),117.51,117.28,103.70,74.81,70.54,58.33,45.66,44.80,44.17,42.08,36.93,36 .75,36.24,34.69,30.62,27.06,26.62,25.06,17.01,15.05,11.73.HRMS(ESI):calcd[M+Na] + forC 32 H 38 FNO6S2 638.2016,found,638.2008.

[0100] Pleuromutilin derivative 22

[0101] 1H NMR (400MHz, CDCl3) δ8.08-8.01(m,1H),7.72(dt,J=6.7,1.3Hz,1H),7.45-7.37(m,2H),7. 14(s,1H),6.41(dd,J=17.5,11.0Hz,1H),5.73(d,J=8.4Hz,1H),5.27(d,J=1.6Hz,1H),5.1 3(dd,J=17.4,1.6Hz,1H),4.02-3.87(m,2H),3.32(s,1H),2.37-2.17(m,3H),2.12-1.96(m ,2H),1.76-1.32(m,11H),1.18-1.04(m,4H),0.84(d,J=7.1Hz,3H),0.70(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.21,166.98,162.41,160.87,153.22,139.02,1 35.11,133.93,132.45,129.99,127.57,123.10,117.50,103.72,74.79, 70.50,58.32,45.64,44.78,44.14,42.06,36.92,36.76,36.21,34.67,3 0.60,27.04,26.59,25.04,17.01,15.05,11.72.HRMS(ESI):calcd[M+Na] + for C 32 H 38 BrNO6S2698.1216,found,698.1207.

[0102] Pleuromutilin derivative 23

[0103] 1H NMR (400MHz, CDCl3) δ8.31(t,J=1.8Hz,1H),8.10(dt,J=7.8,1.3Hz,1H),7.79-7.75(m,1H),7.38(t ,J=7.9Hz,1H),7.11(s,1H),6.42(dd,J=17.4,11.0Hz,1H),5.74(d,J=8.4Hz,1H),5.31(d,J=1.6Hz, 1H),5.14(dd,J=17.5,1.6Hz,1H),4.02-3.87(m,2H),3.33(d,J=6.5Hz,1H),2.38-2.15(m,3H),2.1 0-1.99(m,2H),1.80-1.26(m,11H),1.19-1.04(m,4H),0.85(d,J=7.0Hz,3H),0.72(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.27,166.98,162.33,161.03,153.25,139.03,1 37.21,133.40,130.72,130.48,129.11,122.96,117.54,103.72,74.82, 70.56,58.34,45.67,44.78,44.17,42.09,36.94,36.75,36.23,34.69,3 0.62,27.07,26.62,25.06,17.03,15.07,11.74.HRMS(ESI):calcd[M+H] + for C 32 H 38 BrNO6S2,676.1396,found,676.1344.

[0104] Pleuromutilin derivative 24

[0105] 1H NMR (400MHz, CDCl3) δ8.11-8.01(m,1H),7.55-7.48(m,2H),7.42-7.34(m,1H),7.14(s,1H) ,6.41(dd,J=17.5,11.0Hz,1H),5.73(d,J=8.4Hz,1H),5.29(d,J=1.5Hz,1H),5.13(dd,J=1 7.4,1.6Hz,1H),4.04-3.88(m,2H),3.31(d,J=6.5Hz,1H),2.34-2.14(m,3H),2.09-1.97(m ,2H),1.78-1.29(m,11H),1.17-1.05(m,4H),0.84(d,J=7.0Hz,3H),0.70(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.21,166.98,161.92,160.86,153.23,139.02,1 35.16,133.95,132.45,131.77,128.08,126.99,117.49,103.74,74.80, 70.50,58.32,45.65,44.78,44.14,42.07,36.92,36.76,36.21,34.68,3 0.61,27.04,26.58,25.04,17.00,15.05,11.72.HRMS(ESI):calcd[M+H] + for C 32 H 38 ClNO6S2 632.1901,found,632.1867.

[0106] Pleuromutilin derivative 25

[0107] 1H NMR (400MHz, CDCl3) δ8.04(d,J=8.5Hz,1H),7.54(d,J=2.0Hz,1H),7.36(dd,J=8.5,2.0Hz,1H) ,7.12(s,1H),6.41(dd,J=17.4,11.0Hz,1H),5.74(d,J=8.4Hz,1H),5.30(d,J=1.6Hz,1H),5.14 (dd,J=17.4,1.6Hz,1H),4.01-3.86(m,2H),3.32(t,J=7.4Hz,1H),2.34-2.14(m,3H),2.09-1. 98(m,2H),1.82-1.27(m,11H),1.18-1.04(m,4H),0.85(d,J=7.0Hz,3H),0.70(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.19,166.96,161.07,161.06,153.02,139.94,1 39.06,136.41,133.48,131.77,127.47,126.33,117.50,103.86,74.81, 70.54,58.33,45.66,44.81,44.16,42.08,36.92,36.76,36.23,34.69,3 0.61,27.06,26.62,25.06,17.02,15.06,11.73.HRMS(ESI):calcd[M+Na] + forC 32 H 37 Cl2NO6S2 688.1331,found,688.1309.

[0108] Pleuromutilin derivative 26

[0109] 1H NMR (400MHz, CDCl3) δ8.17-8.05(m,1H),7.61(dt,J=5.5,1.7Hz,1H),7.30-7.18(m,2H),7. 11(s,1H),6.41(dd,J=17.4,11.0Hz,1H),5.74(d,J=8.4Hz,1H),5.29(d,J=3.6Hz,1H),5.1 3(dd,J=17.4,1.5Hz,1H),4.03-3.86(m,2H),3.32(s,1H),2.34-2.16(m,3H),2.11-1.98(m ,2H),1.79-1.32(m,11H),1.17-1.06(m,4H),0.85(d,J=6.9Hz,3H),0.71(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.23, 167.00, 162.69 (d, J = 262.8Hz), 160.91 (d, J = 4.1Hz), 16 0.84,153.22,139.03,135.97(d,J=9.2Hz),132.76,124.44(d,J=3.9Hz),117.65,117. 50,117.43,103.82,74.81,70.51,58.34,45.66,44.80,44.15,42.08,36.94,36.77,36 .23,34.69,30.62,27.05,26.57,25.05,16.99,15.04,11.73.HRMS(ESI):calcd[M+Na] + for C 32 H 38 FNO6S2638.2016,found,638.2019.

[0110] Pleuromutilin derivative 27

[0111] 1H NMR (400MHz, CDCl3) δ8.06-7.94(m,2H),7.47-7.33(m,2H),7.10(d,J=0.8Hz,1H),6.42(dd, J=17.5,11.0Hz,1H),5.74(d,J=8.5Hz,1H),5.31(d,J=1.5Hz,1H),5.14(dd,J=17.4,1.5Hz,1 H),4.07-3.87(m,2H),3.33(d,J=6.6Hz,1H),2.43(s,3H),2.35-2.15(m,2H),2.12-1.97(m,2 H),1.86-1.29(m,11H),1.14(d,J=25.5Hz,4H),0.85(d,J=6.9Hz,3H),0.72(d,J=6.9Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.25,167.03,163.82,160.64,153.72,139.02,13 8.75,135.05,131.02,128.78,128.68,127.75,117.54,103.52,74.83,70. 50,58.35,45.66,44.80,44.16,42.09,36.95,36.80,36.23,34.70,30.63, 27.06,26.61,25.06,21.53,17.02,15.06,11.74.HRMS(ESI):calcd[M+Na] + forC 33 H 41 NO6S2634.2267, found, 634.2226.

[0112] Pleuromutilin derivative 28

[0113] 1H NMR (400MHz, CDCl3) δ7.83-7.74(m,1H),7.66(t,J=2.0Hz,1H),7.46-7.35(m,1H),7.21-7.13(m, 1H),7.09(s,1H),6.41(dd,J=17.5,11.0Hz,1H),5.74(d,J=8.4Hz,1H),5.30(d,J=1.5Hz,1H),5.1 4(dd,J=17.4,1.5Hz,1H),4.04-3.77(m,5H),3.32(d,J=6.7Hz,1H),2.36-2.14(m,3H),2.12-1.97 (m,2H),1.75-1.30(m,11H),1.13(d,J=25.1Hz,4H),0.85(d,J=6.7Hz,3H),0.71(d,J=7.0Hz,3H). 13 C NMR (101MHz, CDCl3) δ217.21,167.00,163.57,160.71,159.92,153.62,13 9.02,130.01,129.90,122.99,120.87,117.51,114.74,103.64,74.80,70. 51,58.33,55.78,45.65,44.80,44.16,42.07,36.93,36.78,36.22,34.68 ,30.61,27.04,26.61,25.05,17.01,15.05,11.72.HRMS(ESI):calcd[M+H] + for C 33 H 41 NO6S2 628.2397,found,628.2347.

[0114] Effect test example 1

[0115] The pleuromutilin derivatives 1 to 28 containing 2-thio-4-thiazolidinone side chains prepared in Example 3 were subjected to antibacterial tests:

[0116] The minimum inhibitory concentration (MIC) of pleuromutilin derivatives 1 to 28 containing 2-thio-4-thiazolidinone side chains against methicillin-resistant Staphylococcus aureus, Staphylococcus aureus (S. aureus-25923), Escherichia coli (Escherichia coli), Streptococcus agalactiae (S. agalactiae) and Streptococcus dysgalactiae (S. dysgalactiae-1) was determined by two-fold dilution method. The results are shown in Table 2. The standard strain was purchased from ATCC, and the clinical strain was preserved by Lanzhou Institute of Animal Husbandry and Veterinary Drugs, Chinese Academy of Agricultural Sciences.

[0117] Table 2 Minimum inhibitory concentration in vitro of pleuromutilin derivatives

[0118]

[0119]

[0120] As can be seen from Table 2, this type of pleuromutilin derivatives have good inhibitory effects on MRSA and S. aureus-25923, among which pleuromutilin derivative 19 has the best antibacterial effect, with MIC value comparable to that of the control drug tylosin, while the inhibitory effect on S. agalactiae and S. dysgalactiae-1 is better than that of tylosin.

[0121] Effect test example 2

[0122] Study on the bactericidal kinetic curve of pleuromutilin derivatives:

[0123] According to the results of the MIC experiment, the truncated pleuromutilin derivative 19 with better activity was screened out, and its bactericidal kinetic curve against MRSA was studied. Preparation of drug solution: The truncated pleuromutilin derivative 19 and tiamulin (T) were prepared into drug solutions with concentrations of 1×MIC, 4×MIC, and 6×MIC, respectively; another bacterial growth tube was taken as the control group. 50μL of bacterial solution was added to tubes with different concentrations, mixed well, and placed in a 37°C shaker for culture. Then, 100μL of samples were taken at 0, 2, 4, 6, 8, 12, and 24h and added to 900μL of normal saline, mixed well, and then 100μL of this 1mL was taken and added to 900μL of normal saline; it was diluted in a 10-fold gradient in sequence. Take 100μL of bacterial solution with different dilution multiples and evenly spread it on the MHA culture medium, and make 3 parallels for each dilution concentration. The culture medium was placed in a 37°C constant temperature incubator for culture for 24h, after which the colonies were counted, and a curve was drawn based on the statistical results. The bactericidal kinetic curve is shown in the figure. Figure 3As shown. Principle of colony count calculation: The number of colonies between 30-300 is an effective dilution. The formula for calculating the number of bacteria in the bacterial solution is: the number of viable bacteria per milliliter of the original bacterial solution = the average number of colonies on 3 replicate plates of the same dilution × dilution factor × 10. Repeat the experiment more than three times. Figure 3 It can be seen that each compound showed concentration dependence. Compared with the control group, the 1×MIC pleuromutilin derivative 19 and the control drug slowed down the bacterial reproduction; at 4×MIC and 6×MIC, the pleuromutilin derivative 19 and the control drug had a bactericidal effect on MRSA.

[0124] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain, It is characterized in that The molecular structure of the compound is shown in the following formula (I): In the formula, the R group is selected from any one of the following groups:

2. A pharmaceutically acceptable salt of the pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain as claimed in claim 1.

3. A method for preparing the pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain as claimed in claim 1, It is characterized in that The following steps are involved: (1) adding pleuromutilin and p-toluenesulfonyl chloride to methyl tert-butyl ether and mixing, adding sodium hydroxide solution dropwise under stirring, and after reflux reaction, cooling, washing and drying the reaction product to obtain an intermediate 1 having a structure shown in formula (II); (2) adding 2-thioxo-4-thiazolidinone to acetonitrile, adding anhydrous potassium carbonate and stirring at room temperature for a certain period of time, then adding the intermediate 1, stirring at room temperature for a certain period of time, and after the reaction is completed, quenching, extracting, drying, and purifying the reaction product to obtain the intermediate 2 with the structure represented by formula (III); (3) adding the intermediate 2 and the group donor acyl chloride to dichloromethane, stirring and reacting at room temperature for a certain time under the catalysis of triethylamine, quenching after the reaction is completed, extracting, drying and purifying the reaction product to obtain a pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain as shown in formula (I); In the formula, the R group is selected from any one of the following groups:

4. The preparation method according to claim 3, It is characterized in that In step (1), the molar volume ratio of pleuromutilin, p-toluenesulfonyl chloride, methyl tert-butyl ether and sodium hydroxide solution is 10-12 mmol: 10-12 mmol: 10-15 mL: 2.5-2.8 mL, and the concentration of the sodium hydroxide solution is 10 mol / L.

5. The preparation method according to claim 3, It is characterized in that In step (2), the molar volume ratio of the intermediate 1, 2-thioxo-4-thiazolidinone, potassium carbonate and acetonitrile is 5-9 mmol: 5-6 mmol: 6-10 mmol: 30-35 mL.

6. The preparation method according to claim 3, It is characterized in that In step (2), the quenching, extraction, drying and purification of the reaction product are as follows: the reactant is quenched with a saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, dried with anhydrous sodium sulfate, and purified by column chromatography according to petroleum ether: ethyl acetate = 3:1 to 2:

1.

7. The preparation method according to claim 3, It is characterized in that In step (3), the molar volume ratio of the intermediate 2, the group donor acyl chloride, triethylamine and dichloromethane is 1-1.2 mmol: 1-1.5 mmol: 2-2.4 mmol: 5-7 mL.

8. The preparation method according to claim 3, It is characterized in that The quenching, extraction, drying and purification methods of the reaction product are as follows: the reactant is quenched with a saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, dried with anhydrous sodium sulfate, and purified by column chromatography according to petroleum ether: ethyl acetate = 4:1 to 2:

1.

9. Use of the pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain as claimed in claim 1 or the pharmaceutically acceptable salt of the pleuromutilin derivative as claimed in claim 2 in the preparation of an antibacterial drug for treating infectious diseases.

10. An antibacterial drug, It is characterized in that The drug comprises the pleuromutilin derivative containing a 2-thioxo-4-thiazolidinone side chain according to claim 1 and one or more pharmaceutically acceptable carriers, excipients or diluents of the pleuromutilin derivative; Or, the drug comprises a pharmaceutically acceptable salt of the pleuromutilin derivative according to claim 2 and one or more pharmaceutically acceptable carriers, excipients or diluents of the salt.

Citation Information

Patent Citations

  • A class of pleuromytilin derivatives, drug composition, synthesis methods and uses thereof

    CN103626693A

  • Antibacterial and antifungal pleuromutilin conjugates

    CN115720579A

  • Pleuromutilin derivative compound as well as preparation method and application thereof

    CN115850137A

  • Pleuromutilin derivative with thiazole side chain as well as preparation method and application of pleuromutilin derivative

    CN117304133A

  • Pleuromutilin derivative containing naphthenic base as well as preparation method and application of pleuromutilin derivative

    CN117417280A